On August 27, 2024, Aclarion, Inc., a Delaware-incorporated company, announced the entry into a subscription agreement with certain accredited investors. Under this agreement, Aclarion agreed to issue and sell 1,000,000 shares of common stock at $0.29 per share, resulting in gross proceeds of $290,000. The shares were offered at-the-market under Nasdaq rules following the Company's Form 1-A Offering Statement, which was filed with the SEC on June 11, 2024, and qualified on June 24, 2024. Additionally, Aclarion entered into a warrant purchase agreement with the investors, issuing warrants to purchase up to 400,000 shares of common stock, exercisable from February 27, 2025, with a five-year term and an initial exercise price of $0.29 per share. These transactions were not brokered, and no fees or commissions will be paid. The company has the option to raise additional proceeds up to approximately $29.39 million under the same terms in the future. The securities were sold without registration under the Securities Act of 1933, in reliance on exemptions provided by Section 4(a)(2) for the Warrants and Regulation A for the Shares.

On August 27, 2024, Aclarion, Inc., a Delaware-incorporated company, announced the entry into a subscription agreement with certain accredited investors. Under this agreement, Aclarion agreed to issue and sell 1,000,000 shares of common stock at $0.29 per share, resulting in gross proceeds of $290,000. The shares were offered at-the-market under Nasdaq rules following the Company's Form 1-A Offering Statement, which was filed with the SEC on June 11, 2024, and qualified on June 24, 2024. Additionally, Aclarion entered into a warrant purchase agreement with the investors, issuing warrants to purchase up to 400,000 shares of common stock, exercisable from February 27, 2025, with a five-year term and an initial exercise price of $0.29 per share. These transactions were not brokered, and no fees or commissions will be paid. The company has the option to raise additional proceeds up to approximately $29.39 million under the same terms in the future. The securities were sold without registration under the Securities Act of 1933, in reliance on exemptions provided by Section 4(a)(2) for the Warrants and Regulation A for the Shares.